PT  - JOURNAL ARTICLE
AU  - Tizita Z. Zeleke
AU  - Qingfei Pan
AU  - Cody Chiuzan
AU  - Maika Onishi
AU  - Mariano J. Alvarez
AU  - Erin Honan
AU  - Min Yang
AU  - Pei Ling Chia
AU  - Partha Mukhopadhyay
AU  - Sean Kelly
AU  - Ruby Wu
AU  - Kathleen Fenn
AU  - Meghna S. Trivedi
AU  - Melissa Accordino
AU  - Katherine D Crew
AU  - Dawn L Hershman
AU  - Matthew Maurer
AU  - Simon Jones
AU  - Andrea Califano
AU  - Kevin Kalinsky
AU  - Jiyang Yu
AU  - Jose Silva
TI  - Network-based assessment of HDAC6 activity is highly predictive of pre-clinical and clinical responses to the HDAC6 inhibitor ricolinostat
AID  - 10.1101/2020.04.23.20066928
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.23.20066928
4099  - http://medrxiv.org/content/early/2020/04/28/2020.04.23.20066928.short
4100  - http://medrxiv.org/content/early/2020/04/28/2020.04.23.20066928.full
AB  - Despite the anticancer activity of pan-histone deacetylase (HDAC) inhibitors, their clinical use has been limited due to toxicity. However, the development of more specific inhibitors that selectively inhibit individual HDACs is emerging as a novel and well-tolerated alternative. Here, we present the results of the first clinical trial evaluating the activity of ricolinostat (the leading HDAC6 inhibitor) in breast cancer (BC) patients.We have developed a computational network-based algorithm to evaluate the activity of the HDAC6 protein, based on the enrichment of its transcriptional targets in differentially expressed genes (HDAC6 score). Through preclinical in vitro and in vivo studies, we confirmed that the HDAC6 score can stratify the sensitivity of BC cells to ricolinostat treatment and may thus have value as a predictive biomarker. Moreover, analysis of ∼3,000 primary human breast cancers showed that ∼30% of them present high HDAC6 scores. Based on these results, we designed a phase Ib clinical trial to evaluate the activity of ricolinostat plus nab-paclitaxel in metastatic BC patients. Study results showed that the two agents can be safely combined, that clinical activity is identified specifically in patients with HR+/HER2-disease, and that the HDAC6 score was predictive of response. Expansion of our analysis to other tumor types identified multiple cohorts enriched in high HDAC6 score samples. These results suggest that the HDAC6 score may provide an effective, CLIA certified predictive biomarker of ricolinostat sensitivity in multiple human cancers.SIGNIFICANCE The clinical use of HDAC inhibitors is hampered by the toxicity associated with blocking multiple HDACs. Here, we show that the specific HDAC6 inhibitor ricolinostat is safe and presents clinical activity in breast cancers and that the HDAC6 score has predictive biomarker potential to identify patients who can benefit from this therapy.Competing Interest StatementDISCLOSURES - MY and SJ were Acetylon employees when this project was initiated. - This research has been partially supported by a sponsor research agreement with Acetylon. - JY was a consultant of the computational analysis for the Phase Ib trial 2015-2017. - MJA is Chief Scientific Officer and equity holder at DarwinHealth, Inc., a company that has licensed some of the algorithms used in this manuscript from Columbia University. AC is founder, equity holder, consultant, and director of DarwinHealth Inc., a company that has licensed some of the algorithms used in this manuscript from Columbia University. Columbia University is also an equity holder in DarwinHealth Inc. Clinical TrialNCT02632071Funding StatementThis research was partially funded through the DOD Breakthrough award 151500 (JS), ALSAC (JY), the St. Jude Comprehensive Cancer Center Developmental Fund (JY), NIH R01 CA153233 (JS), NIH R01 CA153233 –supplement (TZ), R01 GM134382 (JY), U01 CA217858 (AC), S10 OD012351 (AC), and S10 OD021764 (AC), and the Irvin Scholar program (KK).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe RNA-seq data from the clinical trial reported in this paper can be accessed at GEO: (GSE number GSE148623). The codes for the HDAC6 score calculation and other analyses are freely available at https://github.com/jyyulab/HDAC6-score. https://github.com/jyyulab/HDAC6-score